

VANCOTEX

Antibiotics

Recommended treatment of:

Intravenously: complicated skin and soft tissue infections; infections of bones and joints; community-acquired pneumonia (CAP); hospital-acquired pneumonia (HAP) including ventilation-associated pneumonia (VAP); infective endocarditis; acute bacterial meningitis; bacteremia; perioperative antibacterial prophylaxis

Orally: Clostridium difficile infections (CDI)

Route of administration:

i.v.; oral

Active principle:

Vancomycin HCl

Dosage & pack size:

500 mg - Box of 1 vial & Box of 10 vials
1g - Box of 1 vial

Registered for use in:

Italy, Albania, Turkmenistan, Malaysia

For further detailed description, see back side.



Recommended treatment of:

the following infections in all age groups, administered intravenously:

- complicated skin and soft tissue infections
- infections of bones and joints
- community-acquired pneumonia (CAP)
- hospital-acquired pneumonia (HAP), including ventilation-associated pneumonia (VAP)
- infective endocarditis
- acute bacterial meningitis
- Bacteremia that occurs in association or is suspected of being associated with one of the above conditions.

It is also indicated in all age groups for perioperative antibacterial prophylaxis in patients who are at high risk to develop bacterial endocarditis when undergoing major surgery.

Oral administration of Vancomycin is indicated in all age groups for the treatment of *Clostridium difficile* infections (CDI).

The official guidelines on the appropriate use of antibacterial agents should be taken into consideration.

